For Health Care Professionals
HALAVEN for another type of cancer

mBC blog

book

Interested in articles and updates about metastatic breast cancer?

Click here to read the mBC blog!
Live for the moments that haven't happend yet

In a clinical study of more than 750 women, HALAVEN® was compared with other chemotherapies or hormone therapies commonly used to treat metastatic breast cancer (mBC). Although some women lived longer and some women did not live as long, women who were treated with HALAVEN lived, on average, 25% longer (13.2 months vs 10.6 months, respectively) than those who received another chemotherapy or hormone treatment.

Learn more about the results Arrow Image

LEARN ABOUT HALAVEN®

A treatment option for certain patients with metastatic breast cancer (mBC)

Inspire others with your journey on
HALAVEN® (eribulin mesylate) Injection.

Learn more by calling 757-528-3520 or
emailing mBC@mypatientstory.com.

There is a possibility that not all who submit their stories will be selected to participate. Any information provided will be kept in strict confidence according to our Privacy Policy, available at
us.eisai.com/privacy-policy.

Pay as little as $0*

Learn about the $0 Co-Pay Program

Halaven website 0 co pay icon mobile

*The HALAVEN $0 Co-Pay Program assists eligible patients with the out-of-pocket costs of HALAVEN (up to $18,000 per year). Restrictions apply. Visit www.eisaireimbursement.com/patient/halaven/financial-assistance to see the full terms and conditions and eligibility requirements, to learn more about the program, and to download an enrollment form. Eligible commercially insured patients may pay as little as $0 per month, with an annual limit of $18,000.

mbc-blog-img-mob
blog-book

mBC blog

The Doctor Will See You Now: Making the Most of Your Next Virtual Visit

divider

Telehealth is here to stay. Here's what you need to know to make the most of your next virtual doctor's appointment. Read More

Over 80,000 patients in the US have been prescribed HALAVEN for mBC

Learn why

Halaven website prescribed icon mobile

Eligible patients may pay as little as $0*

If you need assistance paying for your medication, we may be able to help.

Learn about the $0 Co-Pay Program Arrow Image

*The HALAVEN $0 Co-Pay Program assists eligible patients with the out-of-pocket costs of HALAVEN (up to $18,000 per year). Restrictions apply. Visit www.eisaireimbursement.com/patient/halaven/financial-assistance to see the full terms and conditions and eligibility requirements, to learn more about the program, and to download an enrollment form. Eligible commercially insured patients may pay as little as $0 per month, with an annual limit of $18,000.

Please review, then scroll to bottom and tap “Continue” to go to site

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Expand Collapse

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider.

All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries.

To report suspected adverse reactions, contact Eisai Inc. at 1-888-274-2378 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This Web site contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent health care decisions, you should always consult with a physician or other health care provider for your, or your loved ones', personal medical needs. Individual responses to treatment may vary.

Eisai logo

HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

© 2023 Eisai Inc. HALA-US4104 us.eisai.com